Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543617 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
A Phase 3 study of Esophageal Squamous Cell Carcinoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
- 20
- Study locations
NCT04543617: Active Phase 3 study of Esophageal Squamous Cell Carcinoma, sponsored by Hoffmann-La Roche.
NCT04543617 is a Phase 3 study of Esophageal Squamous Cell Carcinoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 760 participants, above the 346-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04543617, a Phase 3 study of Esophageal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
- DRUG Tiragolumab Matching Placebo
- DRUG Atezolizumab Matching Placebo
Study Locations (20)
Other
- Instituto de Investigaciones Metabolicas (Idim) - Buenos Aires
- Fundacion Favaloro - Buenos Aires
- Centro Oncologico Riojano Integral (CORI) - La Rioja
- Tiroler Landeskrankenanstalten Ges.M.B.H. - Innsbruck
- Klinikum Klagenfurt am Wörthersee - Klagenfurt
- Ordensklinikum Linz Barmherzige Schwestern - Linz
- AKH - Medizinische Universität Wien - Vienna
- UZ Antwerpen - Edegem
- UZ Leuven Gasthuisberg - Leuven
- CHU de Liège (Sart Tilman) - Liège
- Anyang Tumor Hosptial - Anyang
- Cancer Hospital Chinese Academy of Medical Sciences. - Beijing
- Affiliated Hospital of Bengbu Medical College - Bengbu
- Hunan Cancer Hospital - Changsha
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
Kansas
- Cancer Center of Kansas - Wichita
New York
- Great Lakes Cancer Center - Williamsville
Queensland
- Princess Alexandra Hospital - Woolloongabba
Victoria
- Austin Health - Heidelberg
Western Australia
- St John of God Hospital - Subiaco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 3 |
What the registry record for NCT04543617 still lists
NCT04543617 is an interventional study that assigns participants to a tested intervention. The registered 760 participants enrollment target is mid-sized for trials with a published cap, above the 346-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (120% higher).
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT04543617 names 20 study sites across 7 states, led by Other, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT04543617 about?
NCT04543617 is a clinical study titled "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy". The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following defin...
What is the current status of trial NCT04543617?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2020-09-28. Estimated completion is 2027-03-31.
What conditions does trial NCT04543617 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04543617?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG), Tiragolumab Matching Placebo (DRUG), Atezolizumab Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT04543617?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04543617 being conducted?
This trial has 20 study locations across Florida, Kansas, New York, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04543617's enrollment target sits among peer trials
760 3rd of 22 higher than 20 of 22 other Esophageal Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
RECRUITING · Phase 3
-
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
ACTIVE NOT RECRUITING · Phase 3
-
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
COMPLETED · Phase 3
-
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
- NCT04073706 · 760 participants · Phase 3
Sentinel Node Biopsy in Endometrial Cancer
- NCT05129228 · 760 participants · NA
Optical Coherence Tomography of the Saphenous Vein Graft
- NCT05787821 · 760 participants
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI